15-lipoxygenase (15-LOX, also ALOX15) is a non-heme iron-containing dioxygenase enzyme that stereospecifically inserts molecular oxygen at the 15-position of polyunsaturated fatty acids, functioning as the critical biosynthetic gateway for anti-inflammatory and pro-resolving lipid mediator production. It exists in two isoforms: 15-LOX-1 (reticulocyte-type, predominantly inflammatory contexts) and 15-LOX-2 (epidermis-type, predominantly anti-inflammatory). This enzyme represents the molecular switch point in Lipid mediator class switching—the transition from pro-inflammatory eicosanoids to Specialized pro-resolving mediators (SPMs).
Think of 15-LOX as a precision chemical factory foreman working the night shift after the day crew (the inflammatory crew led by COX-2 and 5-LOX) has finished demolition. While COX-2 and 5-LOX manufacture "demolition molecules" like Prostaglandin E2 and Leukotriene B4 that bring in neutrophils and tear things apart, 15-LOX takes the same raw materials—particularly DHA and arachidonic acid—and runs them through a completely different production line.
Instead of making more inflammatory mediators, 15-LOX creates the "reconstruction foreman molecules": 17-HDHA (the precursor to Protectins and Maresins) and 15-HETE (the precursor to Lipoxins). This is like using the same steel and concrete that built the demolition equipment to instead build scaffolding and reconstruction machinery. The factory doesn't change location—it's still in the same epithelial cells, eosinophils, and macrophages—but the product changes completely based on which enzymatic assembly line is running.
In the airways, 15-LOX is especially concentrated in the respiratory epithelium, acting like a safety valve that prevents demolition from going too far. In the brain, it produces Neuroprotectins (particularly NPD1), functioning as an emergency repair crew for neural tissue under inflammatory attack. The enzyme works best in transcellular biosynthesis—one cell makes the intermediate product (15-HETE or 17-HDHA), which then gets handed off to a neighboring leukocyte that finishes building the final SPM molecule. It's a relay race, not a solo sprint.
15-LOX catalyzes the following primary reactions:
From Arachidonic Acid:
Arachidonic acid → 15-HETE (15-hydroxyeicosatetraenoic acid)
15-HETE then serves as substrate for:
From DHA:
DHA → 17-HDHA (17-hydroxy-docosahexaenoic acid)
17-HDHA → Protectin precursors (including NPD1)
17-HDHA → Maresin precursors (MaR1, MaR2)
graph TD
A[Membrane Phospholipids] -->|PLA2| B[Free AA or DHA]
B -->|15-LOX-1 or 15-LOX-2| C[15-HETE from AA]
B -->|15-LOX| D[17-HDHA from DHA]
C -->|"Transcellular: 5-LOX in PMN"| E[Lipoxin A4/B4]
C -->|COX-2 acetylation aspirin| F[15-epi-Lipoxins]
D -->|Enzymatic rearrangement| G[Protectin D1/NPD1]
D -->|[12-LOX](/en/concepts/12-lox.md) transcellular| H[Maresin 1/2]
E --> I[ALX-FPR2 Receptor]
F --> I
G --> J[Resolution Program Activation]
H --> K[ERV1-ChemR23 Receptor]
I --> L["Neutrophil apoptosis<br/>Macrophage efferocytosis"]
J --> M["Neuroprotection<br/>Anti-apoptosis"]
K --> N["Macrophage phagocytosis<br/>Tissue regeneration"]
-
Iron-Catalyzed Oxygenation:
- Non-heme Fe²⁺/Fe³⁺ at active site
- Removes pro-S hydrogen at carbon-13 of AA (or carbon-15 of DHA)
- Inserts molecular O₂ with S stereochemistry at C-15
- Product: 15S-hydroperoxy intermediate
-
Transcellular Biosynthesis (Critical for Lipoxin Formation):
- Epithelial cell 15-LOX produces 15-HETE from arachidonic acid
- 15-HETE released into extracellular space
- Neutrophil 5-LOX takes up 15-HETE → converts to LXA4
- This epithelial-leukocyte cooperation is essential for Resolution of inflammation
-
Isoform Specificity:
- 15-LOX-1: Predominantly in eosinophils, reticulocytes, macrophages; context-dependent (can be pro-inflammatory in early atherosclerosis via oxidized LDL formation)
- 15-LOX-2: Predominantly in prostate, lung, corneal epithelium; strongly anti-inflammatory; tumor-suppressive
- Upregulated by: IL-4, IL-13 (Th2 cytokines), Glucocorticoid Receptor activation, hypoxia (HIF-1)
- Downregulated by: TNF-α, IL-1β, chronic inflammation, NF-κB activation
- Inhibited by: Corticosteroids (reduce expression), zileuton (inhibits LOX enzymes non-specifically)
- Expression pattern: High in respiratory epithelium, eosinophils, airway smooth muscle, brain hippocampus and cortex
¶ Asthma and Airway Disease
15-LOX expression is paradoxically high in eosinophilic asthma yet reduced in chronic severe asthma. This reflects the dual nature: early in allergic inflammation, eosinophils upregulate 15-LOX to produce Protectins that should limit inflammation—but in chronic disease, this compensatory mechanism fails. Clinically, measuring urinary or plasma levels of 15-HETE and protectin D1 can indicate whether endogenous resolution pathways are functional.
Intervention strategy: Augment failing 15-LOX pathways by:
15-LOX produces neuroprotectin D1 (NPD1) from DHA in neural tissue, particularly hippocampus and cortex. NPD1 levels are severely reduced in Alzheimer's Disease brains (down to 20-30% of age-matched controls). NPD1:
- Inhibits A-beta fibres oligomerization
- Reduces IL-1β and TNF-α in microglia
- Promotes BDNF expression
- Protects synaptic integrity via anti-apoptotic signaling (upregulates Bcl-2, downregulates Bax)
Clinical threshold: Plasma DHA <4% of total fatty acids = insufficient substrate for NPD1 synthesis → accelerated cognitive decline risk.
Intervention: High-dose DHA (1-2g/day) combined with Curcumin (which upregulates 15-LOX expression) and intermittent Hypoxia stress response training (upregulates HIF-1 → 15-LOX).
15-LOX-1 has a context-dependent dual role here. In early atherosclerosis, it oxidizes LDL cholesterol, promoting foam cell formation (pro-atherogenic). But in later stages, it produces lipoxins that promote plaque stability and Macrophage Polarization toward M2 phenotype (anti-atherogenic). This is an example of antagonistic pleiotropy—the same enzyme is harmful early, protective late.
Clinical application: In Metabolic syndrome with Low-Grade Inflammation, measure plasma Lipoxins (LXA4 >10 pg/mL = functional resolution pathway). If low despite adequate omega-3 fatty acids, suspect transcellular biosynthesis failure—the epithelial-leukocyte handoff is broken.
15-LOX is the immune system's attempt to protect the brain and lungs (high-value organs) from collateral damage during inflammation. From a selfish systems lens (Selfish Brain, selfish immune system), the brain demands NPD1 production during neuroinflammation—hence why 15-LOX is highly expressed in hippocampus. When chronic stress depletes DHA stores (via cortisol-driven lipolysis and oxidative consumption), NPD1 synthesis fails → hippocampal vulnerability → Depression, Anxiety, cognitive decline.
Metamodel connection: This is Metamodel 5 (Resolution of inflammation) intersecting with Metamodel 3 (Brain-gut axis). When gut dysbiosis reduces SCFA production → reduced BDNF → reduced hippocampal DHA uptake → impaired 15-LOX substrate availability → failed resolution → chronic inflammation in CNS.
- Two isoforms: 15-LOX-1 (reticulocyte, dual role) and 15-LOX-2 (epidermis, anti-inflammatory)
- Produces 15-HETE from arachidonic acid → precursor for Lipoxins via transcellular biosynthesis with 5-LOX
- Produces 17-HDHA from DHA → precursor for Protectins (NPD1) and Maresins
- Highest expression: Respiratory epithelium, eosinophils, airway smooth muscle, brain (hippocampus, cortex), prostate
- NPD1 levels reduced 70-80% in Alzheimer's Disease compared to age-matched controls
- Upregulated by IL-4 and IL-13 (Th2 cytokines) and Glucocorticoid Receptor activation
- Downregulated by TNF-α and IL-1β in chronic inflammation → vicious cycle
- Clinical biomarker: Urinary 15-HETE >500 pg/mg creatinine = active lipoxin biosynthesis pathway
- Aspirin paradox: Acetylated COX-2 + 15-LOX → aspirin-triggered lipoxins (ATL) → more potent SPMs
- Transcellular biosynthesis essential for lipoxin production—epithelial 15-LOX + neutrophil 5-LOX cooperation
- Substrate dependency: Requires plasma DHA >4% and arachidonic acid >6% for optimal SPM production
- Gene polymorphisms: ALOX15 SNPs associated with reduced lipoxin production in asthma and increased atherosclerosis risk
- Specialized pro-resolving mediators (SPMs) — 15-LOX is the primary biosynthetic enzyme initiating SPM production from omega-3 substrates
- Lipid mediator class switching — represents the molecular switch from pro-inflammatory eicosanoids to pro-resolving mediators
- Protectins — produces 17-HDHA, the immediate precursor for protectin D1 and neuroprotectin D1 (NPD1)
- Maresins — generates 17-HDHA which is converted to maresin-1 and maresin-2 via 12-LOX transcellular biosynthesis
- Lipoxins — produces 15-HETE from arachidonic acid, enabling lipoxin A4/B4 synthesis when handed to neutrophil 5-LOX
- DHA — primary omega-3 substrate for neuroprotectin and maresin biosynthesis; requires plasma DHA >4% for adequate 15-LOX activity
- 5-LOX — partner enzyme in transcellular biosynthesis; 15-LOX produces intermediate, 5-LOX completes lipoxin synthesis
- 12-LOX — parallel lipoxygenase pathway; collaborates with 15-LOX for maresin synthesis from 17-HDHA
- COX-2 — when acetylated by aspirin, works with 15-LOX to produce aspirin-triggered lipoxins (15-epi-LXA4)
- eosinophils — highest 15-LOX-1 expression among leukocytes; produces protectins in allergic inflammation
- macrophages — expresses 15-LOX during M2 polarization; essential for producing SPMs that drive Efferocytosis
- Resolution of inflammation — 15-LOX products (lipoxins, protectins, maresins) are the molecular mediators of active resolution programs
- asthma — 15-LOX produces airway-protective protectins and lipoxins; expression paradoxically high in eosinophilic asthma but fails in severe chronic asthma
- Alzheimer's Disease — NPD1 (15-LOX product) reduced 70-80% in AD brains; protects against amyloid-beta toxicity and neuroinflammation
- omega-3 fatty acids — substrate dependency; 15-LOX cannot function without adequate EPA and DHA availability
- chronic inflammation — TNF-α and IL-1β downregulate 15-LOX expression, creating vicious cycle where inflammation suppresses its own resolution
- CNS injury — produces neuroprotectin D1 (NPD1) which inhibits neuronal apoptosis, reduces microglial activation, promotes synaptic repair
- epithelial cells — respiratory epithelium highly expresses 15-LOX; produces 15-HETE that is released to leukocytes for lipoxin completion
- arachidonic acid — omega-6 substrate for 15-HETE production; balance with DHA determines SPM product profile
- HIF-1 — hypoxia-inducible factor upregulates 15-LOX expression; connects Cold exposure and Intermittent Living to SPM production
- IL-4 — Th2 cytokine that strongly upregulates 15-LOX expression in macrophages and epithelial cells
- BDNF — neuroprotectin D1 (15-LOX product) upregulates BDNF expression in hippocampus; bidirectional relationship
- Lipoxins — end products of 15-LOX/5-LOX transcellular cooperation; bind ALX-FPR2 receptor to stop neutrophil recruitment
- Atherosclerosis — dual role: 15-LOX-1 oxidizes LDL (pro-atherogenic early) but produces lipoxins (anti-atherogenic late)
- neuroinflammation — 15-LOX produces NPD1 which inhibits NF-κB in microglia, reducing IL-1β and TNF-α production
- Metabolic syndrome — reduced 15-LOX expression correlates with insulin resistance and adipose tissue inflammation
- PLA2 — phospholipase A2 releases arachidonic acid and DHA from membrane phospholipids, providing substrate for 15-LOX
- Neutrophil apoptosis — lipoxins (15-LOX products) accelerate neutrophil apoptosis and clearance, essential for resolution
- M2 macrophages — M2 polarization upregulates 15-LOX expression; SPM production is hallmark of M2 phenotype
- Glucocorticoid Receptor — glucocorticoids upregulate 15-LOX expression, contributing to anti-inflammatory effects beyond simple suppression